Moderna, Merck Cancer Vax Gives Hope
AI Summary
Moderna and Merck have developed an mRNA cancer vaccine demonstrating promising results in preventing melanoma recurrence in a large late-stage trial. This breakthrough represents a significant advancement in cancer treatment technology amid prior challenges related to post-pandemic backlash and technological hurdles.
Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marvel." (Source: Bloomberg)